MILAN, Italy and NEW YORK , April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the
MILAN and NEW YORK , March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S.
MILAN, N.Y. , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC
• Signs of intra-tumor pro-inflammatory state in patients • Temferon™ induced immune system reset in preclinical studies • Macrophage and T cell profiles in patients’ tumor microenvironment echo preclinical findings MILAN, Italy and NEW YORK , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science
Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of €34.7 million as of June 30, 2022 , providing a cash runway until the end of 2024 €1.8 million unrealized
MILAN, Italy and NEW YORK , Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several
MILAN, Italy and NEW YORK , Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several
Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets MILAN, Italy , July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in
MILAN, Italy and NEW YORK , May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May
Extensive experience in business development with AstraZeneca and GSK MILAN, Italy and NEW YORK , May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer,
